Organization
Odense University Hospital, Odense, Denmark
2 abstracts
Abstract
Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial.Org: Department of Oncology, Odense University Hospital, Odense, Denmark, Vejle Hospital, Vejle, Denmark, Aarhus University Hospital, Aarhus, Denmark, Odense University Hospital, Odense, Denmark, Odense University Hospital, Odense C, Denmark,
Abstract
BASEMENT MEMBRANE SEROLOGICAL MARKERS OF COLLAGEN TYPE IV AND LAMININ REMODELING ARE DIFFERENTIALLY EXPRESSED IN SLEOrg: Odense University Hospital, Department of Rheumatology, Odense, Denmark, Nordic Bioscience, Herlev, Denmark, Odense University Hospital, Odense, Denmark,